Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue

Asian Journal of Andrology

Volumn 14, Issue 2, 2012, Pages 316-319

  Wu, Zong Lin ^a   Yuan, Ya ^a   Geng, He ^a   Xia, Shu Jie ^b  

^a People s Hospital of Shanghai Putuo District   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

androgen; androgen receptor; benign prostatic hyperplasia; immunohistochemistry; inflammation

Indexed keywords

ANDROGEN RECEPTOR; CD20 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, CD4; ANTIGENS, CD8; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES;

EID: 84858067155     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.154     Document Type: Article

References (26)

1. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403-15.
2. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20 Suppl 3: S11-8.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9. (Pubitemid 14026148)
4. Xia SJ, Xu XX, Teng JB, Xu CX, Tang XD. Characteristic pattern of human prostatic growth with age. Asian J Androl 2002; 4: 269-71.
5. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98. (Pubitemid 37542987)
6. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-16. (Pubitemid 46436310)
7. Zhou Y, Xiao XQ, Chen LF, Yang R, Shi JD et al. Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl 2009; 11: 451-9.
8. Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol 2008; 108: 254-60. (Pubitemid 351179630)
9. St Sauver JL, Jacobsen SJ. Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. Curr Prostate Rep 2008; 6: 67-73.
10. Curren J. CLIA Compliance Handbook: The Essential Guide for the Clinical Laboratory. New York: Institute of Management & Administration; 2007.
11. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immunomediated inflammation. J Immunol 2009; 182: 4056-64.
12. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2009; 32: 1-15.
13. Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43: 194-9.
14. Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008; 9: 272-8.
15. Sciarra A, di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A et al. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007; 52: 964-72. (Pubitemid 47332058)
16. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-9. (Pubitemid 43041217)
17. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107.
18. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58. (Pubitemid 34553191)
19. di Silverio F, Gentile V, de Matteis A, Mariotti G, Giuseppe V et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164-75. (Pubitemid 36221971)
20. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-84.
21. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-80.
22. Xia SJ, Xu CX, Tang XD, Wang WZ, Du DL. Apoptosis and hormonal milieu in ductal system of normal prostate and benign prostatic hyperplasia. Asian J Androl 2001; 3: 131-4.
23. Xia SJ, Hao GY, Tang XD. Androgen receptor isoforms in human and rat prostate. Asian J Androl 2000; 2: 307-10.
24. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann NY Acad Sci 2009; 1155: 43-56.
25. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009; 63: 142-8.
26. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001; 7: 1773-81. (Pubitemid 32708648)